Catabasis Pharmaceuticals Analysis

Catabasis Pharmaceuticals is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Catabasis Pharmaceuticals delisted stock analysis is to determine its intrinsic value, which is an estimate of what Catabasis Pharmaceuticals is worth, separate from its market price. There are two main types of Catabasis Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Catabasis Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Catabasis Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Catabasis Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Catabasis Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Catabasis Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Catabasis Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

Catabasis Stock Analysis Notes

About 55.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.98. Some equities with similar Price to Book (P/B) outperform the market in the long run. Catabasis Pharmaceuticals recorded a loss per share of 9.99. The entity had not issued any dividends in recent years. The firm had a split on the 20th of August 2021. Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company was incorporated in 2008 and is based in Boston, Massachusetts. Catabasis Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people. For more info on Catabasis Pharmaceuticals please contact Jill Milne at 617 349 1971 or go to http://www.catabasis.com.

Catabasis Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Catabasis Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Catabasis Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Catabasis Pharmaceuticals is not yet fully synchronised with the market data
Catabasis Pharmaceuticals has some characteristics of a very speculative penny stock
Catabasis Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 250 K. Net Loss for the year was (221.83 M) with profit before overhead, payroll, taxes, and interest of 500 K.
Catabasis Pharmaceuticals currently holds about 139.52 M in cash with (34.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.88.

Catabasis Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 657.14 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Catabasis Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Catabasis Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Catabasis Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio Comparator Now

   

Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Consideration for investing in Catabasis Stock

If you are still planning to invest in Catabasis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catabasis Pharmaceuticals' history and understand the potential risks before investing.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.